RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group - PubMed (original) (raw)
Clinical Trial
. 2011 Apr 1;29(10):1364-72.
doi: 10.1200/JCO.2010.30.7926. Epub 2011 Feb 22.
Lars Bullinger, Richard F Schlenk, Andreas S Zimmermann, Jürgen Röck, Peter Paschka, Andrea Corbacioglu, Jürgen Krauter, Brigitte Schlegelberger, Arnold Ganser, Daniela Späth, Andrea Kündgen, Ingo G H Schmidt-Wolf, Katharina Götze, David Nachbaur, Michael Pfreundschuh, Heinz A Horst, Hartmut Döhner, Konstanze Döhner
Affiliations
- PMID: 21343560
- DOI: 10.1200/JCO.2010.30.7926
Clinical Trial
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group
Verena I Gaidzik et al. J Clin Oncol. 2011.
Abstract
Purpose: To evaluate frequency, biologic features, and clinical relevance of RUNX1 mutations in acute myeloid leukemia (AML).
Patients and methods: Diagnostic samples from 945 patients (age 18 to 60 years) were analyzed for RUNX1 mutations. In a subset of cases (n = 269), microarray gene expression analysis was performed.
Results: Fifty-nine RUNX1 mutations were identified in 53 (5.6%) of 945 cases, predominantly in exons 3 (n = 11), 4 (n = 10), and 8 (n = 23). RUNX1 mutations clustered in the intermediate-risk cytogenetic group (46 of 640, 7.2%; cytogenetically normal, 34 of 538, 6.3%), whereas they were less frequent in adverse-risk cytogenetics (five of 109, 4.6%) and absent in core-binding-factor AML (0 of 77) and acute promyelocytic leukemia (0 of 61). RUNX1 mutations were associated with MLL-partial tandem duplications (P = .0007) and IDH1/IDH2 mutations (P = .03), inversely correlated with NPM1 (P < .0001), and in trend with CEBPA (P = .10) mutations. RUNX1 mutations were characterized by a distinct gene expression pattern; this RUNX1 mutation-derived signature was not exclusive for the mutation, but also included mostly adverse-risk AML [eg, 7q-, -7, inv(3), or t(3;3)]. RUNX1 mutations predicted for resistance to chemotherapy (rates of refractory disease 30% and 19%, P = .047, for RUNX1-mutated and wild-type patients, respectively), as well as inferior event-free survival (EFS; P < .0001), relapse-free survival (RFS, P = .022), and overall survival (P = .051). In multivariable analysis, RUNX1 mutations were an independent prognostic marker for shorter EFS (P = .007). Explorative subgroup analysis revealed that allogeneic hematopoietic stem-cell transplantation had a favorable impact on RFS in RUNX1-mutated patients (P < .0001).
Conclusion: AML with RUNX1 mutations are characterized by distinct genetic properties and are associated with resistance to therapy and inferior outcome.
Trial registration: ClinicalTrials.gov NCT00146120 NCT00151242.
Similar articles
- RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. Mendler JH, et al. J Clin Oncol. 2012 Sep 1;30(25):3109-18. doi: 10.1200/JCO.2011.40.6652. Epub 2012 Jul 2. J Clin Oncol. 2012. PMID: 22753902 Free PMC article. Clinical Trial. - IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD. Marcucci G, et al. J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368543 Free PMC article. - Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD. Marcucci G, et al. J Clin Oncol. 2008 Nov 1;26(31):5078-87. doi: 10.1200/JCO.2008.17.5554. Epub 2008 Sep 22. J Clin Oncol. 2008. PMID: 18809607 Free PMC article. - Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L. Port M, et al. Ann Hematol. 2014 Aug;93(8):1279-86. doi: 10.1007/s00277-014-2072-6. Epub 2014 May 7. Ann Hematol. 2014. PMID: 24801015 Review. - Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics.
Gaidzik V, Döhner K. Gaidzik V, et al. Semin Oncol. 2008 Aug;35(4):346-55. doi: 10.1053/j.seminoncol.2008.04.005. Semin Oncol. 2008. PMID: 18692685 Review.
Cited by
- Inhibition of NF-κB Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics.
Reikvam H. Reikvam H. Cells. 2020 Jul 12;9(7):1677. doi: 10.3390/cells9071677. Cells. 2020. PMID: 32664684 Free PMC article. - Clinical Implications of Inflammation in Acute Myeloid Leukemia.
Récher C. Récher C. Front Oncol. 2021 Feb 22;11:623952. doi: 10.3389/fonc.2021.623952. eCollection 2021. Front Oncol. 2021. PMID: 33692956 Free PMC article. Review. - RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.
Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B, Dufour A, Schneider F, Schneider S, Kakadia PM, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK. Greif PA, et al. Haematologica. 2012 Dec;97(12):1909-15. doi: 10.3324/haematol.2012.064667. Epub 2012 Jun 11. Haematologica. 2012. PMID: 22689681 Free PMC article. - Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification.
Liu T, Rao J, Hu W, Cui B, Cai J, Liu Y, Sun H, Chen X, Tang Y, Chen J, Wang X, Wang H, Qian W, Mao B, Guo S, Wang R, Liu Y, Shen S. Liu T, et al. Nat Commun. 2022 Mar 28;13(1):1640. doi: 10.1038/s41467-022-29336-y. Nat Commun. 2022. PMID: 35347147 Free PMC article. - A critical role of RUNX1 in governing megakaryocyte-primed hematopoietic stem cell differentiation.
Wang C, Tu Z, Cai X, Wang W, Davis AK, Nattamai K, Paranjpe A, Dexheimer P, Wu J, Huang FL, Geiger H, Huang G, Zheng Y. Wang C, et al. Blood Adv. 2023 Jun 13;7(11):2590-2605. doi: 10.1182/bloodadvances.2022008591. Blood Adv. 2023. PMID: 36661340 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous